Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF)
Steven Nathan (Falls Church, United States of America), Steven Nathan, Carlo Albera, Williamson Bradford, Ulrich Costabel, Roland Du Bois, Elizabeth Fagan, Robert Fishman, Ian Glaspole, Marilyn Glassberg, Kenneth Glasscock, Lisa Lancaster, David Lederer, Zhengning Lin, Carlos Pereira, Jeffrey Swigris, Dominique Valeyre, Paul Noble, Athol Wells
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Steven Nathan (Falls Church, United States of America), Steven Nathan, Carlo Albera, Williamson Bradford, Ulrich Costabel, Roland Du Bois, Elizabeth Fagan, Robert Fishman, Ian Glaspole, Marilyn Glassberg, Kenneth Glasscock, Lisa Lancaster, David Lederer, Zhengning Lin, Carlos Pereira, Jeffrey Swigris, Dominique Valeyre, Paul Noble, Athol Wells. Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2015; 46: Suppl. 59, 4491
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: